PeptideStack
5.2kquestions
20kanswers
220users

What is a sensible monitoring routine for semaglutide over four weeks?

Asked 4 May 2025Modified 10 months agoViewed 9.2k times
12

Details up front: semaglutide · four weeks.

The failure mode I am trying to avoid is making this decision emotionally.

I have twelve months in view and I would like the plan to survive that long.

What would you do, and what would make you change course?

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
plateau
plateau

A stall in progress: distinguishing adaptive thermogenesis from measurement error from adherence drift, how long to observe before changing…

36 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
shareeditfollowflag
LM
askedlucia_marchetti19k274 May 2025
Same laboratory as last time? Between-laboratory differences are larger than most of the changes people chase. – b_delacroix 21 hours ago
8Can you say how far out of range rather than that it was flagged? The flag is a threshold, not a finding. – tandem_gradient 8 months ago
add a comment

5 Answers

Accepted answer first, then by votes
119

Accepted answer

4 weeks is 28 days: 4 weekly administrations, and 1 four-week dose steps. Two draws fit inside that span honestly — baseline before the first dose, one repeat — plus a written trigger for anything extra. A third is a budget rather than a plan at 4 weeks. The constraint is that the markers worth drawing move more slowly than 28 days. An HbA1c integrates roughly the preceding ninety days, so a repeat at day 28 is still about 69 per cent pre-treatment blood and mostly reports where you started. Lipids and hepatic enzymes settle faster and are worth the repeat at 28 days. A renal panel earns its place at baseline specifically so that an early eGFR change has something to be a change from. Fix the repeat date at the start, in writing. A monitoring plan decided after a result arrives is not a plan, and nothing here is medical advice.

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Headline results, principal programmes

TrialAgentnDurationPrimary result
STEP 1Semaglutide 2.4 mg1,96168 wk−14.9 % vs −2.4 % weight
STEP 2Semaglutide 2.4 mg, T2DM1,21068 wk−9.6 % vs −3.4 % weight
SURMOUNT-1Tirzepatide 5/10/15 mg2,53972 wk−15 / −19 / −21 % weight
SURMOUNT-4Tirzepatide, withdrawal67088 wkContinued loss vs substantial regain
SELECTSemaglutide 2.4 mg17,604~40 moMACE HR 0.80 (0.72–0.90)
FLOWSemaglutide 1.0 mg, CKD3,533~3.4 yrRenal composite reduced; stopped early
SURMOUNT-OSATirzepatide, OSA46952 wkAHI reduced with and without PAP

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

Decide the action for each result before you order the test.

edited 18 Sept 2025 by nadia_kowalczyk — added a caveat about sampling

shareimprove this answerflag
NK
answered · acceptednadia_kowalczyk20k2827 Aug 2025
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
46

The relevant statistical point is that a ninety-five per cent reference interval means one analyte in twenty will read out of range in a healthy person by construction.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Keep the full report, not the number. You will need the units and the interval later.

shareimprove this answerflag
CI
answeredcake_intact17k2711 May 2025
34

Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

shareimprove this answerflag
VR
answeredv_ramaswamy68k575 Aug 2025
8The one-in-twenty out-of-range arithmetic should be printed at the top of every panel report. – laminar_bench 9 months ago
7Worth flagging that a mild enzyme elevation with a normal bilirubin is a different object from a rising one. – tabular_nums 7 months ago
add a comment
27

Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

shareimprove this answerflag
DB
answeredDr_Signe_Baldursdottir29k2716 Aug 2025
2Does this hold for a non-fasting draw, or does the triglyceride figure make that a different conversation? – dana_wexler 3 months ago
add a comment
22

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

shareimprove this answerflag
HV
answeredh_villanueva70k4813 Jun 2025
3Minor: haemolysis inflates potassium enough to cause a fright over what is a handling artefact. – Dr_Lena_Ostrowska 2 months ago
2Is the assay method stated on your report? Two immunoassays for the same analyte do not agree with each other. – kwn_analytical 19 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.